Correlation Between AN2 Therapeutics and Pharvaris

Can any of the company-specific risk be diversified away by investing in both AN2 Therapeutics and Pharvaris at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining AN2 Therapeutics and Pharvaris into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between AN2 Therapeutics and Pharvaris BV, you can compare the effects of market volatilities on AN2 Therapeutics and Pharvaris and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in AN2 Therapeutics with a short position of Pharvaris. Check out your portfolio center. Please also check ongoing floating volatility patterns of AN2 Therapeutics and Pharvaris.

Diversification Opportunities for AN2 Therapeutics and Pharvaris

0.54

Correlation Coefficient

AN2 Therapeutics  Pharvaris

Very weak diversification

The 3 months correlation between AN2 and Pharvaris is 0.54. Overlapping area represents the amount of risk that can be diversified away by holding AN2 Therapeutics and Pharvaris BV in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pharvaris BV and AN2 Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on AN2 Therapeutics are associated (or correlated) with Pharvaris. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pharvaris BV has no effect on the direction of AN2 Therapeutics i.e., AN2 Therapeutics and Pharvaris go up and down completely randomly.

Pair Corralation between AN2 Therapeutics and Pharvaris

Given the investment horizon of 90 days AN2 Therapeutics is expected to under-perform the Pharvaris. But the stock apears to be less risky and, when comparing its historical volatility, AN2 Therapeutics is 1.01 times less risky than Pharvaris. The stock trades about -0.19 of its potential returns per unit of risk. The Pharvaris BV is currently generating about -0.16 of returns per unit of risk over similar time horizon. If you would invest  2,190  in Pharvaris BV on November 29, 2024 and sell it today you would lose (644.00) from holding Pharvaris BV or give up 29.41% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

AN2 Therapeutics  vs.  Pharvaris BV

AN2 Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days AN2 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pharvaris BV

Risk-Adjusted Performance

Very Weak

Over the last 90 days Pharvaris BV has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with AN2 Therapeutics and Pharvaris

The main advantage of trading using opposite AN2 Therapeutics and Pharvaris positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if AN2 Therapeutics position performs unexpectedly, Pharvaris can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharvaris will offset losses from the drop in Pharvaris' long position.

The idea behind AN2 Therapeutics and Pharvaris BV pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.